Hetrombopag in Promoting Platelet Engraftment After Auto-HSCT in Children With Neuroblastoma
Recruiting
N/A
Interventional Study
Delayed Platelet Engraftment
Neuroblastoma
Autologous Hematopoietic Stem Cell Transplantation
No Placebo Group
Every participant receives an active treatment — no one gets a placebo.
At a Glance
- Age
- Up to 18
- Sex
- Any
- Study type
- Interventional
- Purpose
- Prevention
- Participants needed
- 30 (estimated)
- Sponsor
- Beijing Children's Hospital · Other
Think this trial could be right for you?
Answer a few quick questions to see if you may meet the eligibility requirements.
Check Your Eligibility
About This Trial
The goal of this clinical trial is to learn if hetrombopag promotes platelet engraftment in neuroblastoma children undergoing autologous hematopoietic stem cell transplantation. The main question it aims to answer is: · Does drug hetrombopag promote platelet engraftment? Participants will take hetrombopag every day for 6 weeks or until platelet \> 100\*10\^9/L.
Trial Locations
Loading…
Loading trial locations…
Eligibility Criteria
Inclusion Criteria:
* Age\<18 years old;
* Diagnosed as neuroblastoma;
* ECOG ≤ 2;
* First time receiving autologous hematopoietic stem cell transplantation;
* The subjects or their legal guardians agree to participate and sign the informed consent form.
Exclusion Criteria:
* ALT/AST \> 3 ULN, or…
Contacts